Tag: acceleron pharma
November 8, 2019
Celgene Receives FDA Approval for REBLOZYL
REBLOZYL is the first FDA-approved treatment of anemia in adults with beta thalassemia that require red blood cell transfusions. April 5, 2019
Celgene and Acceleration Pharma Announce Submission of Luspatercept Biologics License Application to FDA
Celgene (NASDAQ:CELG) and Acceleron Pharma (NASDAQ:XLRN) have announced that Celegene has submitted a biologics license application for luspatercept, which is... June 29, 2018